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1.1 SMALL BOWEL CARCINOMA: EPIDEMIOLOGY 
 
Small bowel carcinoma (SBC) is a remarkably rare neoplasm; its incidence is, 
however, increasing and is reported to be 7.3 cases per million people per year 
(1,2; Figure 1). Overall, only 2% of all malignant neoplasms of the 
gastrointestinal (GI) tract and 0.6% of all new cancer cases occur in the small 
intestine. SBCs represent the second most common neoplasm of the small 
intestine, accounting for about 40% of all cancers of this organ, whereas 
neuroendocrine neoplasms currently constitute the dominant histotype (2). The 
incidence rates vary with geographic regions, with higher rates in North America 
and Western Europe and lower rates in Asian countries (3). SBCs occur more 
frequently in men than in women and affect blacks more often than whites (3). 
The median age at SBC diagnosis ranges from 55 to 65 years (4,5).  
More than half of all SBCs arise in the duodenum, even though this organ 
constitutes only 4% of the entire length of the small intestine (6). This finding 
suggests that bilio-pancreatic secretions may play a role in their 
etiopathogenesis. A smaller percentage of tumors arise in the jejunum, 
particularly in the first 30 cm distal to the ligament of Treitz. Ileal carcinomas are 
the least common. Occasionally, an SBC arises in a Meckel diverticulum.  
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Figure 1. Epidemiology of small bowel tumors from the NCDB (1985–2005) and 
US SEER (1973–2005) cohorts and Connecticut Tumor Registry 1980–
2000.2,3,6 a | Most adenocarcinomas and carcinoids are present in the 
duodenum and the ileum, respectively. b | The proportion of histological tumor 
subtypes found in the small bowel varies depending on the anatomic location of 
the small bowel. c | The incidence of small bowel tumors, especially carcinoids, 
adenocarcinomas and lymphomas has increased in the past few years. 
Abbreviations: NCDB, National Cancer Data Base; SEER, Surveillance, 
Epidemiology and End Results. From Raghav, K. & Overman, M. J. Nat. Rev. 
Clin. Oncol. 10, 534–544 (2013). 
 
Epithelial neoplasms develop far less frequently in the small intestine than in the 
colon, even though the small intestine has a larger epithelial surface area and a 
higher rate of cellular turnover. Several hypotheses have been proposed to 
explain the relative rarity of small bowel adenomas and carcinomas (7). First, 
the transit time of substances through the small intestine is relatively short 
compared with the colon, resulting in brief contact time between the mucosa 
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and the luminal contents. Second, unlike the colon, the small intestine does not 
contain a large quantity of bacteria, that are known to convert bile salts into 
potential carcinogens. Moreover, in the healthy small bowel, immune 
homeostasis prevails with a gut microbiota that is in balance with intestinal 
epithelial cells producing antimicrobial peptides and releasing immune 
modulatory cytokines that drive naïve dendritic cells to differentiate into 
tollerogenic dendritic cells. Third, the luminal contents are more liquid in the 
small bowel than in the colon. As a result, potentially carcinogenic luminal 
substances are diluted and the risk of mechanical trauma is reduced. Fourth, 
the small intestine is rich in lymphoid tissue, which provides a potentially high 
level of immune surveillance against neoplastic cells. Finally, the presence of 
Paneth cells, that are specialized secretory epithelial cells located in the small 
intestine on the bottom of the crypts of Lieberkühn, play a pivotal role in the 
maintenance of the intestinal barrier function by secreting large quantity of 
antimicrobial peptides such as defensins and lysozyme. 
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1.2 CLINICAL FEATURES OF SMALL BOWEL CARCINOMA 
 
SBCs are generally asymptomatic in their early stages, but occult 
gastrointestinal bleeding may occur, leading to anaemia. Patients may have 
presenting symptoms of intestinal obstruction, intussusception, or perforation. 
Duodenal tumors may obstruct the bile duct and cause jaundice.  
The development of newer techniques such as video capsule endoscopy, 
double-balloon enteroscopy, and computed tomographic (CT) enterography 
may explain the increasing incidence and allow a better localization of SBC, 
which may appear as an annular lesion, a discrete nodular mass, or an 
ulcerative lesion, often with corresponding narrowing of the lumen. 
 
1.3 PATHOLOGIC AND MOLECULAR FEATURES OF SMALL 
BOWEL CARCINOMA 
 
On macroscopy, SBC may have a flat, annular, stenotic, ulcerative, or polypoid 
gross appearance (Figure 2). Larger lesions tend to be found in the more distal 
portions of the small bowel, because lesions in that area often fail to produce 
symptoms until they are advanced. Direct spread may cause adherence to 
adjacent structures in the peritoneal cavity, usually a loop of small intestine. 
Lymphatic spread to regional lymph nodes is common. 
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Figure 2. SBC gross appearance. A) Jejunal resection specimen demonstrating 
a circumferential SBC constricting the small intestinal lumen. B) An SBC 
demonstrating a polypoid growth pattern. From:  Odze and Goldblum “Surgical 
Pathology of the GI Tract, Liver, Biliary Tract and Pancreas” 3rd Edition 
 
The World Health Organization’s (WHO) histologic classification of epithelial 
tumors of the small intestine is summarized in Figure 3. Tumors arising in the 
ampulla of Vater are separately classified from those arising elsewhere in the 
small intestine because significant treatment and prognostic differences exist for 
this group of tumors. Most SBCs are adenocarcinomas with variable degrees of 
mucin production. The grading system for SBC is identical to that used for the 
large bowel and the majority of SBCs are moderately differentiated (Figure 4). 
However, approximately 20% of SBCs are poorly differentiated. Rarer SBC 
histotypes include mucinous carcinomas, signet ring cell carcinomas, 
adenosquamous or squamous carcinomas and medullary carcinomas. 
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Figure 3. 2010 WHO Classification of epithelial tumors of the Small Bowel. 
 
Figure 4. Moderately differentiated adenocarcinoma of the small intestine. 
 
SBCs show more variable expression of cytokeratin 7 (CK7) than do colorectal 
carcinomas (CRC). In one study, diffuse positive CK7 immunoreactivity was 
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identified in 54% of nonampullary SBCs, and focal positivity was present in the 
remaining 46% of cases (8). In the same study, 67% of cases expressed CK20. 
Expression of MUC1, MUC2, and MUC5AC occurs in 53%, 57% and 40% of 
SBCs, respectively (9). 
Most SBCs, like CRC, are believed to arise from an adenoma–carcinoma 
sequence in which genetic alterations progressively accumulate, leading to 
cancer development (Figure 5). Residual adenomatous tissue adjacent to foci 
of invasive SBC is seen in about 50% of duodenal SBCs. Histologically, small 
bowel adenomas are similar to those of the colon, but with a high propensity to 
be more villous or tubule-villous in architecture. 
 
Figure 5. The adenoma–carcinoma sequence in small bowel carcinoma. a | A 
number of molecular alterations are implicated in small bowel carcinogenesis. b 
| Risk of progression of adenoma to malignancy depends on the tumor size and 
histology. From Raghav, K. & Overman, M. J. Nat. Rev. Clin. Oncol. 10, 534–
544 (2013). 
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Several notable molecular similarities and differences between SBC and CRC 
exist. KRAS mutations, which occur commonly in CRC and are thought to 
represent an early change in the adenoma–carcinoma sequence in the colon, 
are also found in SBC, occurring in 14% to 83% of cases (10, 11). The reported 
wide variation in mutation frequency in different studies may be related to the 
fact that combined tumors from duodenal and other small-intestinal locations 
are often included in the analyses. In general, KRAS mutations are more 
frequent in duodenal neoplasms than in those that arise in other small bowel 
sites. BRAF V600E mutations are extremely rare in SBC (12). The most 
remarkable molecular finding in SBCs is that loss-of-function mutations in the 
APC tumor-suppressor gene, which is the most common event in the early 
development of CRC, do not have a pivotal role in the development of SBC 
(13). Although somatic mutations are found in 80% of sporadic CRC, only about 
5% of sporadic SBCs (spo-SBCs) harbor this defect. Despite the absence of 
APC gene mutations, upregulation of the Wnt/β-catenin pathway as indicated by 
aberrant protein expression of β-catenin is still seen in 40–48% of SBCs (12, 
13).  Mutations in CTNNB1 (the gene coding for β-catenin), have been reported 
in 14% of patients with SBC (six out of 42 tested cases) (14-16). Interestingly, 
the mutation spectrum is also different, with gain-of-function missense point 
mutations being common in CRC, but only large insertions or deletions reported 
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in SBC. p53 overexpression and TP53 mutations are seen in 40% of SBCs, 
indicating the pivotal role of p53 in this disease (10).  
Microsatellite instability (MSI) and loss of mismatch-repair (MMR) proteins are 
seen in 18–35% of SBCs compared to approximately 15% of CRCs (17, 18). 
Moreover, as with CRC, a SBC subset show methylation abnormalities. In a 
study of 37 SBCs, 24 tumors were found to show abnormal methylation patterns 
in at least one of the loci studied (17). Eleven tumors were classified as CpG 
island methylator phenotype-high (CIMP-H), and 13 were CIMP-low. As in the 
colon, CIMP-H status was strongly associated with the high-frequency MSI 
phenotype. 
A recent genomic characterization of a large series of 7559 SBC patients 
found that the most common genetic alterations affected TP53 (58.4%), KRAS 
(53.6%), APC (26.8%), SMAD4 (17.4%), and PIK3CA (16.1%) and 
demonstrated distinct differences in comparison with either colorectal cancer or 
gastric carcinoma (19). In addition, genomic profiling identified potentially 
targetable genetic alterations in most SBC cases (91%). In this regard, Laforest 
et al. found ERBB2 alterations in 12% of their SBCs, through mutations (7 
cases) or amplifications (3 cases) (20). 
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1.4. TREATMENT AND PROGNOSIS OF SMALL BOWEL 
CARCINOMA 
 
Surgery and systemic chemotherapy is the mainstay of therapy for locoregional 
and metastatic disease, respectively (3). Surgical resection with adequate 
lymph-node sampling is critical for long-term survival in resectable disease. 
SBC prognosis is poor (21). In one study, the median overall survival time was 
20.1 months, with a 5-year overall survival rate of 26% (22). The primary reason 
is that patients are often asymptomatic until late during the disease, and 
metastases are often present at the time of diagnosis. Tumor stage is the single 
most important prognostic factor in SBC (22). Other factors associated with 
poor prognosis include poor differentiation, positive margins, duodenal location, 
male sex, black ethnicity and older age. High lymph-node ratio (>50–75%) and 
a low number of assessed lymph nodes have been significantly associated with 
decreased survival (23). 
 
1.5 SMALL BOWEL CARCINOMA PREDISPOSING 
CONDITIONS 
 
Although SBCs are often sporadic, several predisposing conditions (Figure 6), 
including hereditary syndromes (e.g. familial adenomatous polyposis, Lynch 
syndrome, Peutz-Jeghers syndrome and juvenile polyposis syndrome) and 
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immune-mediated intestinal disorders, such as celiac disease (CD) and Crohn’s 
disease (CrD), have been identified (3). 
 
 
Figure 6. Predisposing conditions for small bowel carcinoma development. 
From: Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary 
Tract and Pancreas, 3rd Edition. 
 
CD is a chronic enteropathy induced, in genetically susceptible individuals, by 
gluten ingestion (24) that affects 1% of western population (25). It is a 
predisposing condition for SBC as well as for many other malignant neoplasms, 
such as enteropathy-associated T-cell lymphoma, and esophageal carcinoma 
(26, 27).  In a recent meta-analysis of eight studies including 79.991 CD 
patients and 75 SBCs associated with CD (CD-SBCs), SBC risk of CD subjects 
has been estimated to be 14-fold higher than that of the general population (27) 
and in one study of 175 patients with SBC, 13% had celiac disease (28). The 
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diagnosis of CD preceded that of SBC in 63% of these patients who followed a 
gluten-free diet in most cases (29). CD-SBCs frequently arise in the jejunum 
and may be multifocal. CD-SBCs were reported to harbor a high incidence of 
MMR deficiency (29,30) and to follow the CpG island methylator (CIMP) 
pathway (31).  
In CrD, which is a relapsing transmural inflammatory bowel disease (IBD) 
resulting from an inappropriate immune response to commensal microrganisms, 
SBC risk is 33-fold higher (32) than that of the general population. SBCs 
associated with CrD (CrD-SBCs) are reported to account for 7% of all SBCs 
(32). Risk factors for development of SBC in individuals with CrD include 
surgically excluded loops of small bowel, chronic fistulous disease, male sex 
and a long CrD duration. In one study, adenocarcinoma risk was found to be 
lower in CrD patients who had undergone small bowel resection or who had 
used salicylates for longer than 2 years (33). In comparison with spo-SBC and 
CD-SBC, CrD-SBC tends to involve more frequently the ileum than the 
duodenal-jejunal tract. It may be very difficult to macroscopically identify the 
tumor in an area of severe CrD. In these patients, SBCs typically arise in the 
setting of intraepithelial neoplasia or dysplasia (flat or polypoid) rather than in 
preexisting adenomas. However, the diagnosis of dysplasia is sometimes 
difficult because of recurrent and persistent inflammatory changes associated 
with the underlying IBD. Histologically, the diagnosis of dysplasia is based on 
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identification of a combination of architectural and cytologic features. 
Architectural alterations may result in a configuration that resembles adenoma. 
Cytologic abnormalities consist primarily of cellular and nuclear pleomorphism, 
nuclear hyperchromasia, loss of polarity, and nuclear stratification. Most CrD-
SBCs develop in areas of macroscopically identifiable IBD. 
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2. AIMS 
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Several studies are available concerning SBC clinical, histologic, phenotypic 
and molecular features (8, 17, 20, 34, 35). These studies, however, deal mostly 
with spo-SBC cases. Information concerning CD-SBC and CrD-SBC is limited 
to a few small series or case reports (29, 30, 31, 36, 37), and both the histologic 
features and the molecular landscape of these rare cancers are still largely 
unknown. 
On this basis the primary aim of this thesis was to comparatively assess 
histopathological, phenotypic, molecular and prognostic features of SBC in a 
relatively large multicentre collection of patients with sporadic SBC and SBC 
associated with either CD or CrD.  
Secondary aims were (a) to look for any prognostic influence of 
histopathological structure and tumor cell phenotype in our whole SBC series; 
b) to gain new insights into SBC histogenesis, with special reference to the 
carcinogenetic process at work in the inflamed non-tumor mucosa of CD-SBC 
or CrD-SBC; and c) to search for the presence of Epstein-Barr virus (EBV), a 
recognized oncogenic agent, in tumor cells of SBCs, especially of those 
associated with CrD, because EBV is detected at high frequency in non-
neoplastic intestinal mucosa of IBD patients. 
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3. MATERIALS AND METHODS 
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3.1 STUDY POPULATION 
 
This retrospective study included 51 patients with pathologically-confirmed 
primary non-familial, non-ampullary SBC associated with either CD (n=26) or 
CrD (n=25), who had surgical resection and complete survival data from 20 
tertiary referral Italian Celiac and/or IBD Centres participating in the Small 
Bowel Cancer Italian Consortium, i.e. Pavia (Coordinating Centre), Aviano, 
Bologna, Brescia, Cagliari, Genova, Firenze, L’Aquila, Modena, Milano-Ca’ 
Granda, Milano-Sacco, Napoli, Padova, Palermo-Cervello, Palermo-Giaccone, 
Roma-S. Filippo Neri, Roma-Tor Vergata, Roma-Umberto I, Roma S. Eugenio, 
Torino. 
Demographic and clinical data of CD and CrD patients are reported in Table 1 
and Table 2, respectively. CD diagnosis was based on serum IgA anti-
endomysial and anti-tissue transglutaminase antibody positivity associated with 
typical duodenal histopathological lesions (Marsh type 3) (24). In 5 cases (19%), 
CD diagnosis was concomitant to that of SBC. The remaining 21 cases were 
under a strict gluten free-diet at SBC diagnosis except for three patients with 
poor compliance. Only one of 26 CD patients was diagnosed as refractory CD 
type 1. 
CrD diagnosis was ascertained according to the usual clinical criteria (38), and 
the site and extent of the disease were confirmed by endoscopy, histology and 
imaging. In three patients (12%), CrD diagnosis was simultaneous to that of 
SBC. Sixteen out of 25 CrD patients (64%) had fibro-stenosing disease, 5 
(20%) were predominantly inflammatory while 4 (16%) had penetrating behavior 
at SBC diagnosis. Only 4 CrD patients were under immunomodulatory therapy. 
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Twenty-five patients with sporadic SBC (spo-SBC), i.e. without a concomitant 
intestinal immune-mediated disorder, were included as a control group. In spo-
SBC cases, CD was excluded (serum IgA anti-endomysial and anti-tissue 
transglutaminase antibody negativity with normal serum total IgA), while CrD 
was ruled out by the absence of classic clinical and biochemical features. Re-
examination of the sporadic surgical specimens further confirmed the lack of 
histological lesions indicative of either CD or CrD. The main exclusion criteria 
for all SBC subgroups were Lynch syndrome, Peutz-Jeghers syndrome, familial 
adenomatous polyposis and juvenile polyposis. These hereditary syndromes 
were excluded in all cases by negative family and personal history, colonoscopy 
and histologic evaluation of the surgical specimens, and, in MSI SBC cases, by 
the presence of MLH1 promoter methylation, as well. Neuroendocrine 
neoplasms were also excluded. 
This study was approved by the Ethics Committee of the San Matteo Hospital 
Foundation of Pavia. 
 
3.2 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
 
Tissue samples were fixed in 4% formaldehyde and processed in paraffin wax. 
Four μm-thick sections were stained with haematoxylin–eosin (H&E) for 
morphological evaluation. All cases were investigated for histologic type and 
grade, according to the WHO classification (39), lymphovascular invasion and 
all the parameters required to fulfil the criteria of the AJCC staging system (40). 
In addition, SBCs were also classified, on the basis of their histologic structure, 
as a) glandular type (if >70% of the tumor exhibited glandular pattern), b) 
diffuse/poorly cohesive cell type (signet ring cell cancers or cancers showing 
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diffusely infiltrating, poorly cohesive cells, dispersed in a frequently 
desmoplastic stroma as single elements or as small aggregates with little to no 
gland formation, in >70% of the tumor), c) mixed type (characterized by a 
combination of both glandular and poorly cohesive cell/desmoplastic patterns, 
with at least 30% each, within the same tumor) and solid cancers (when they 
showed almost exclusively a solid or trabecular pattern) (41-43). Among solid 
cancers, d) medullary-type cancers (characterized by tumor cells exhibiting 
prominent infiltration by T lymphocytes and a pushing margin) were 
distinguished from the e) non-medullary solid cases lacking these features (42). 
All cases were also checked for the presence of adjacent dysplastic lesions and 
metaplastic features of the uninvolved mucosa. 
For immunohistochemistry, four μm-thick sections were incubated at 4°C for 18-
20 hours with specific antibodies directed against: the gastric foveolar cell 
marker MUC5AC (monoclonal, clone CLH2, Abcam), the pancreatobiliary duct 
marker cytokeratin (CK) 7 (monoclonal, clone OV-TL 12/30, Dako), the pyloric 
and Brunner’s gland marker MUC6 (monoclonal, clone CLH5, Novocastra), as 
well as against intestinal differentiation markers including the caudal type 
homeobox transcription factor 2 (CDX2, monoclonal, clone DAK-CDX2, Dako), 
the goblet cell marker MUC2 (monoclonal, clone Ccp58, Santa Cruz 
Biotechnology), CK20 (monoclonal, clone Ks20.8, Dako) and the small bowel 
brush border marker CD10 (monoclonal, clone 56C6, Dako). In addition, 
immunoreactions for C-terminal β-catenin (monoclonal, clone 14/Beta-Catenin, 
BD), for the transcription factor Sex-determining Region Y-Box 9 (SOX-9, 
polyclonal, Millipore), for the mismatch repair proteins including MLH1 
(monoclonal, clone ES05, Dako), MSH2 (monoclonal, clone FE11, Dako), 
MSH6 (monoclonal, clone EP49, Dako) and PMS2 (monoclonal, clone EP51, 
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Dako), for p53 protein (monoclonal, clone DO7, Dako), for the neuroendocrine 
marker chromogranin-A (monoclonal, clone LK2H10, Ventana), for CD3 
(polyclonal, Dako), CD8 (polyclonal, Dako), for human epidermal growth factor 
receptor 2 (HER2, monoclonal, Leica Biosystem, Newcastle, UK) and for 
Programmed Death-Ligand 1 (PD-L1, monoclonal, clone E1L3N, Cell Signaling 
Technology, Danvers, MA) were also performed. Immunoreactions were 
developed using 0.03% 3,3’ diaminobenzidine tetrahydrochloride and sections 
were then counterstained with Harris’ hematoxylin. 
For the assessment of tumor cell phenotype, only cases with at least 10% 
immunoreactive cells were regarded as positive with the exception of CDX2, for 
which a cut-off of 20% was applied (44). Cases with nuclear accumulation of C-
terminal β-catenin in at least 10% of dysplastic/tumor cells was recorded as 
positive and were also tested for loss of nuclear expression of N-terminal β-
catenin (monoclonal, clone E247, Abcam). Only relatively strong nuclear SOX-9 
immunoreactivity, with the same intensity as the deepest intestinal crypt cells, 
was regarded as positive. Tumor-infiltrating lymphocytes (TILs) were stained 
using CD3 and CD8 antibodies and counted in ten consecutive high-power 
fields (HPFs), selecting areas containing the maximum number of neoplastic 
cells with minimal reactive stroma and necrosis and evaluating only 
lymphocytes in direct contact with tumor cells, i.e. “intraepithelial” TILs. A tumor 
was also classified as having “high TIL density” when the mean number of TILs 
per HPF was greater than 15 for CD3 or greater than 9.5 for CD8 (45). 
Immunostaining of MMR proteins (MLH1, MSH2, MSH6 and PMS2) in tumor 
cells was evaluated as positive (retained expression) or negative (absent 
expression): only tumors showing absence of nuclear staining of all neoplastic 
cells in the presence of an internal positive control (intra-tumor stromal and 
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inflammatory cells or non-tumor mucosa) were considered negative. 
Carcinomas or dysplastic lesions were considered p53 positive when more than 
50% of tumor cells showed strong nuclear p53 immunoreactivity, in line with 
previous studies (46). Scoring of HER2 immunostaining was conducted 
according to published criteria for gastric cancer (47). 
 
3.3 MICROSATELLITE INSTABILITY ANALYSIS 
 
Tumor DNA was obtained from formalin-fixed and paraffin-embedded tissues 
using three representative 8 μm-thick sections of tumor samples. DNA was 
extracted after manual microdissection using a QIAamp DNA formalin-fixed, 
paraffin-embedded tissue kit according to the manufacturer’s protocol (Qiagen, 
Hilden, Germany). Microsatellite instability analysis was performed using a 
pentaplex panel of monomorphic mononucleotide repeats (BAT25, BAT26, NR-
21, NR-22 and NR-24) by the ABI PRISM 310 Genetic Analyzer (Applied 
Biosystems, Foster City, CA) (48). 
 
3.4 MLH1 METHYLATION ANALYSIS 
 
MLH1 methylation status was examined by pyrosequencing in SBC cases 
exhibiting loss of MLH1 immunohistochemical expression. Bisulfite modification 
of genomic DNA (300 ng) was performed with EZ DNA Methylation-GoldTM Kit 
(Zymo Research, Irvine, CA) according to the manufacturer’s 
recommendations. A region of 84 nucleotides inside the Deng C-region of 
MLH1 promoter (49) was analysed by pyrosequencing according to the protocol 
previously reported (50). Analytical sensitivity and linearity of the assay was 
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assessed using a serial dilution of fully methylated DNA and unmethylated DNA 
(Chemicon International Inc., Billerica, MA). A sample was classified as 
methylated when the mean of all the five cytosines was greater than 8%. Mono- 
or bi-allelic methylations of the MLH1 promoter were also validated by MS-
MLPA using the SALSA MS-MLPA ME011 MMR kit (MRC-Holland, Amsterdam, 
The Netherlands). MS-MLPA analysis was performed according to the 
manufacturer’s recommendations and a methylation ratio was calculated using 
Coffalyser V7 software (MRC Holland). 
 
3.5 GENE MUTATION ANALYSIS 
 
Mutation analysis of KRAS, NRAS, BRAF and PIK3CA genes was performed 
using the Sequenom MassARRAY system (Diatech Pharmacogenetics, Jesi, 
Italy), based on matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry, together with the Myriapod Colon Status Kit (Diatech 
Pharmacogenetics). This kit includes a series of multiplexed assays designed to 
interrogate a total of 153 non-synonymous hotspot mutations in the four genes. 
DNA amplification was done in a 5-μL reaction mixture containing 10 to 20 ng of 
tumuor DNA. PCR, Shrimp Alkaline Phosphatase reaction and single base pair 
extension steps were carried out following the protocols provided by Diatech 
Pharmacogenetics. Completed genotyping reactions were spotted in nanoliter 
volumes onto a matrix-arrayed silicon SpectroCHIP with 96 elements using the 
MassARRAY Nanodispenser (Diatech Pharmacogenetics). SpectroCHIP was 
analysed using the Sequenom MassARRAYs Analyzer 4 spectrometer and the 
spectra were processed by the MassARRAY Typer Analyzer 4.0 software 
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(Diatech Pharmacogenetics). All automated system mutation calls were 
confirmed by manual review of the spectra. We investigated TP53 mutations at 
exons 5-8 which correspond to the core domain involved in protein-protein 
interaction (tetramerization) and in binding to DNA and represent the region 
where the vast majority of TP53 mutations are detected. Briefly, exons 5-8 were 
amplified by PCR using sets of primers reported in IARC TP53 database tools 
(http://p53.iarc.fr/ProtocolsAndTools.aspx). In detail, we used primer pairs that 
amplify small (poor DNA quality) fragments (IARC code: P-312 and P-271 for 
exon 5; P-239 and P-240 for exon 6; P-237 and P-238 for exon 7; P-316 and P-
319 for exon 8). PCR products were subjected to automated sequencing by ABI 
PRISM 310 (Applied Biosystems, Foster City, CA). All mutated cases were 
confirmed at least twice starting from independent PCR reactions. In each case, 
the detected mutation was confirmed in the sequence as sense and antisense 
strands.  
 
3.6 HER2 FLUORESCENT IN SITU HYBRIDIZATION  
 
HER2 amplification by fluorescent in situ hybridization (FISH) was performed 
with a PathVysion HER-2 DNA probe Kit (Abbott Laboratories, Des Plaines, IL) 
in SBC cases showing equivocal (weak-to-moderate, 2+) or positive (intense, 
3+), circumferential, basolateral or lateral HER2 immunoreactivity in at least 
10% of tumor cells. The HER2 amplification scoring was performed by counting 
HER2 and CEN17 signals from 40 to 100 nuclei/tissue sample. Non-tumor 
(normal small bowel) mucosa was used as internal negative control. Samples 
with a HER2/CEN17 ratio ≥2.0, or ratio <2 with >10% of neoplastic cells 
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showing HER2≥6 signals/nuclei, or presence of a pattern of HER2 signals in 
clusters, were considered amplified. 
 
3.7 EPSTEIN-BARR VIRUS ENCODED RNAS (EBER) IN SITU 
HYBRIDIZATION 
 
As EBV is reported to be the most prevalent viral infection in non-neoplastic 
mucosa of IBD, especially in steroid-refractory cases (51), all CrD-SBCs and 11 
CD-SBCs were also analysed for the expression of EBER, a marker of latent 
phase EBV infection. The formalin-fixed, paraffin-embedded tissue sections 
were pretreated with proteinase K (DAKO) for 30 min at room temperature, then 
hybridized with a FITC-labeled peptic nucleic acid probe complementary to 
EBV-encoded RNAs (EBER-1 and 2; DakoCytomation, Glostrup, Denmark) and 
incubated overnight at 55 °C. After washing in restricting conditions for 35 min, 
the hybridized cells were visualized with an in-situ hybridization detection kit 
(K5201; DAKO) according to the manufacturer’s instructions. The sections were 
then counterstained with Kernechtrot, dehydrated through graded alcohols, 
immersed in xylene and mounted with a permanent medium. The present in-situ 
hybridization method stained the nuclei of EBV-infected cells dark blue, while 
the nuclei of non-infected cells appeared red. Specificity controls were 
performed by omitting the EBER probe and by running in parallel EBV positive 
and negative gastric cancers characterized in a previous investigation (42). 
3.8 STATISTICAL ANALYSIS 
 
This is a retrospective, longitudinal study. The follow-up extended from the date 
of surgery to the date of death or last follow-up. Descriptive statistics were 
computed as median and 25th-75th percentiles for continuous variables and as 
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counts and percentage for categorical variables. Median follow-up and its 
interquartile range (25th-75th) were computed by means of the inverse Kaplan 
Meier method. The Kruskall Wallis test and the Fisher exact test were used to 
compare continuous and categorical variables, respectively, between types of 
neoplasms. Cumulative survival was plotted according to the Kaplan Meier 
method. Death rates per 100-person year (95% CI) were also computed as 
summary measures. The association between candidate prognostic factors and 
tumor-related death was estimated by means of Cox regression. Multivariable 
models including non-collinear variables with p<0.1 at univariable analysis were 
fitted. The choice of variables to be included in the multivariable model was 
decided a priori and was based on the biological knowledge of the tumor. Model 
discrimination was assessed with the Harrell’s c statistic (the closer to 1, the 
better) and calibration with the shrinkage coefficient (the closer to 1, the better). 
Hazard ratios (HR) and their 95% confidence intervals (95% CI) were 
computed. The proportional hazard assumption was tested, based on 
Schoenfeld residuals. Model discrimination was assessed with the Harrell’s c 
statistic (the closer to 1, the better) and calibration with the shrinkage coefficient 
(the closer to 1, the better). A 2-sided p-value <0.05 was considered statistically 
significant. For post-hoc comparisons Bonferroni correction was applied. Stata 
14.1 (StataCorp, College Station, TX) was used for computation. 
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Table 1. Clinical and pathological features of 26 patients affected by celiac disease-associated small bowel carcinoma 
Pt Sex Age at CD dgn (yrs) 
Age at SBC 
dgn(yrs) 
CD duration at 
SBC dgn (mo) 
Diet status at SBC dgn SBC  
location Histologic type 
SBC 
grade 
SBC 
stage 
Follow-up 
(mo) Outcome 
 
1 
 
M 
 
56 
 
60 
 
48 
 
Strict GFD 
 
Jejunum 
 
ADCA/usual 
 
G2 
 
IIB 
 
107 
 
Alive 
2 F 66 68 22 Strict GFD Jejunum ADCA/usual G3 I 163 Alive 
3 F 38 39 12 Strict GFD (RCD type1) Jejunum ADCA/usual G2 IIA 29 Alive 
4 F 47 48 12 Strict GFD Jejunum ADCA/usual G2 IIA 41 Alive 
5 F 63 64 12 Strict GFD Jejunum ADCA/usual G2 IIA 41 Alive 
6 F 42 42 0 No GFD Duodenum ADCA/signet ring cell G3 IIIB 20 Alive 
7 F 68 72 43 Strict GFD Jejunum ADCA/usual G2 IIA 123 Alive 
8 F 34 59 300 Poor compliance to GFD Jejunum ADCA/usual G2 I 208 Alive 
9 F 46 46 5 Strict GFD Jejunum ADCA/usual G2 IV 13 Dead 
10 F 38 38 1 Strict GFD Jejunum ADCA/usual G3 IIIB 27 Alive 
11 F 7 28 252 Strict GFD Jejunum ADCA/usual G2 IIA 167 Alive 
12 F 42 42 0 No GFD Ileum ADCA/usual G2 IIA 75 Alive 
13 F 41 43 24 Strict GFD Ileum ADCA/usual G2 I 210 Alive 
14 F 53 55 31 Poor compliance to GFD Jejunum ADCA/usual G2 IIB 31 Alive 
15 M 51 51 0 No GFD Ileum ADCA/usual G3 IIA 113 Alive 
16 F 61 66 60 Strict GFD Jejunum Medullary G3 IIIA 74 Alive 
17 M 30 30 0 No GFD Duodenum ADCA/usual G2 IIIB 21 Alive 
18 M 43 54 132 Strict GFD Jejunum ADCA/usual G2 IIA 22 Alive 
19 F 56 67 132 Poor compliance to GFD Jejunum Medullary G3 IIA 168 Alive 
20 M 53 53 0 No GFD Duodenum ADCA/mucinous G3 IIIB 34 Alive 
21 M 79 80 12 Strict GFD Jejunum Medullary G3 IIB 71 Alive 
22 M 28 40 144 Strict GFD Duodenum ADCA/usual G2 IIIA 31 Dead 
23 M 31 32 7 Strict GFD Duodenum Medullary G3 IIA 48 Alive 
24 M 66 72 72 Strict GFD Duodenum ADCA/signet ring cell G3 NA 12 Dead 
25 M 65 66 12 Strict GFD Jejunum ADCA/usual G2 IIB 54 Alive 
26 F 52 54 24 Strict GFD Jejunum ADCA/usual G3 IV 17 Dead 
 ADCA, adenocarcinoma; CD, celiac disease; dgn, diagnosis; F, female; GFD: gluten-free diet; M, male; NA, not applicable; Pt, patient; RCD: refractory celiac disease; SBC, small 
bowel carcinoma. 
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 Table 2. Clinical and pathological features of 25 patients affected by Crohn’s disease-associated small bowel carcinoma 
 
 
  
Pt Sex Age at CrD dgn (yrs) 
Age at SBC 
dgn (yrs) 
CrD duration at 
SBC dgn (mo) 
CrD 
phenotype* 
Previoustherapy 
for CrD 
SBC 
location Histologic type 
SBC 
grade 
SBC 
stage 
Follow-up 
(mo) Outcome 
 
1 
 
M 
 
84 
 
84 
 
0 
 
A3L1B3 
 
No 
 
Ileum 
 
ADCA/signet ring cell 
 
G3 
 
IIIA 
 
1 
 
Dead 
2 M 69 69 1 A3L1B2 5-ASA, CS Ileum ADCA/signet ring cell G3 IIIB 3 Dead 
3 M 43 59 312 A3L1B2 5-ASA, CS Ileum ADCA/usual G2 IIIA 33 Dead 
4 F 52 55 52 A3L1B2 AZA, Infliximab,5-ASA, CS Ileum ADCA/usual G3 IIIB 7 Dead 
5 M 27 33 72 A2L1B1 Infliximab, 5-ASA, CS Ileum ADCA/usual G3 IV 21 Dead 
6 F 40 44 48 A2L3B2 5-ASA, CS Ileum ADCA/usual G2 IV 3 Dead 
7 M 55 73 216 A3L1B3 5-ASA, CS, AB Ileum ADCA/usual G3 IIIB 37 Dead 
8 F 24 54 360 A2L1 B3 5-ASA, CS, AB Ileum ADCA/usual G2 IIIA 61 Alive 
9 M 27 68 492 A2L1 B1 5-ASA, CS Ileum ADCA/usual G3 IV 2 Dead 
10 M 37 54 204 A2L1 B3 5-ASA, CS, AB Ileum ADCA/signet ring cell G3 IIIA 5 Dead 
11 M 69 69 0 A3L1B2 No Ileum ADCA/usual G2 IIA  155 Alive 
12 F 58 59 1 A3L1B2 5-ASA, CS Ileum ADCA/signet ring cell G3 IIA 30 Dead 
13 M 27 50 276 A2L4B2 5-ASA, CS Duodenum ADCA/signet ring cell G3 IIB 23 Dead 
14 M 29 60 372 A2L1B2 5-ASA Ileum ADCA/usual G2 IV 9 Dead 
15 F 52 62 120 A3L1B1 AZA, 5-ASA, CS Ileum ADCA/usual G3 IIB 72 Dead 
16 M 56 56 3 A3L1B1 5-ASA, CS Ileum ADCA/usual G3 IV 16 Alive 
17 M 77 77 0 A3L1B2 No Ileum ADCA/usual G2 IIA 117 Dead 
18 M 50 77 324 A3L1B2 5-ASA, CS Ileum ADCA/usual G2 IIIA 0 Dead 
19 M 51 52 11 A3L1B2 AZA, 5-ASA, CS Ileum ADCA/usual G2 IIA 12 Alive 
20 F 52 77 300 A3L1B2 AZA, 5-ASA, CS Ileum ADCA/usual G2 I 0 Dead 
21 F 22 44 264 A2L3B2 5-ASA, CS Ileum ADCA/usual G2 I 204 Alive 
22 F 58 58 3 A3L1B2 5-ASA, CS Ileum ADCA/usual G2 IIA 81 Alive 
23 M 39 63 252 A2L1B2 AZA, 5-ASA, CS Jejunum ADCA/usual G2 IIA 24 Alive 
24 M 50 63 156 A3L1B2 5-ASA, CS Ileum Medullary G3 IIIB 20 Alive 
25 F 33 57 288 A2L3B3 AZA, Infliximab, 5-ASA, CS, AB Ileum ADCA/usual G2 I 73 Alive 
AB: antibiotics; ADCA, adenocarcinoma; 5-ASA: 5-aminosacylic; AZA, azathioprine; CrD, Crohn’s disease; CS: corticosteroids; dgn, diagnosis; F, female; M, male;  NA, not applicable;  Pt, patient; SBC, small 
bowel carcinoma. *Montreal classification. 
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4. RESULTS 
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4.1 CLINICO-PATHOLOGICAL CHARACTERIZATION OF SMALL 
BOWEL CARCINOMAS 
 
In total, we analysed a cohort of 76 patients, 26 with CD-SBC, 25 with CrD-SBC 
and 25 with spo-SBC (Table 3). Median age at the time of cancer diagnosis in 
the CD-SBC subgroup was significantly lower than that of spo-SBC patients and 
median duration of intestinal disease at SBC diagnosis was significantly lower in 
CD-SBCs in comparison to CrD-SBCs. A higher proportion of females was 
found in CD-SBCs in comparison to the other two subgroups, although the 
difference did not reach statistical significance. As expected, the most common 
small bowel subsite was the ileum for CrD-SBCs, while in both CD-SBCs and 
spo-SBCs it was the jejunum. No significant difference was observed among 
the three subgroups in terms of stage and presence of local lymph nodes or 
distant metastases. SBC diagnosis was suspected or obtained preoperatively in 
all CD-SBC and spo-SBC patients, in contrast to only 7 of 25 CrD-SBC cases 
(28%). Nevertheless, the proportion of SBC patients in stage I-II with more than 
7 lymph nodes assessed was comparable between the three subgroups. 
 
Patients were followed-up for a median of 71 months (25th-75th: 30-123). Overall 
survival curves show the prognostic effect of the clinical subgroup at univariable 
analysis. A significantly worse overall survival was observed in CrD-SBC cases 
in comparison to CD-SBC (HR 6.29, 95% CI 2.10-18.85, p=0.003) but not to 
spo-SBC (HR 1.75, 95% CI, 0.68-4.54, p=0.460) cases. Spo-SBC patients 
showed a trend for worse overall survival in comparison to CD-SBC cases, 
although the difference did not reach statistical significance (HR 3.59, 95% CI 
0.88-14.57, p=0.087) (Figure 7A). Median survival was 28 months for CrD-SBC 
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and 72 months for spo-SBC patients, while it was not evaluable for CD-SBC 
cases as the cumulative survival was >50%. Five-year overall survival rates 
were 83% (95% CI, 61-93), 38% (95% CI, 18-58) and 54% (95% CI, 29-73) for 
CD-SBC, CrD-SBC and spo-SBC, respectively. No survival difference was 
found between CrD patients under immunomodulatory therapy or not (p=0.581). 
Stage I-II patients showed a significantly better overall survival in comparison to 
stage III-IV cases at univariable analysis. Stage-, age- and sex- adjusted 
multivariable analysis confirmed the significant prognostic power of both the 
clinical subgroup and stage (Table 4, model 1). Cancer-specific survival was 
significantly worse in CrD-SBC patients in comparison to CD-SBC (HR 5.65, 
95% CI: 1.86-17.18, p=0.007) but not to spo-SBC (HR 1.56, 95% CI: 0.59-4.17, 
p=0.829) cases. Spo-SBC patients showed a trend towards a worse cancer-
specific survival in comparison to CD-SBC cases, although the difference did 
not reach statistical significance (HR 3.64, 95% CI: 1.16-11.46, p=0.082, after 
Bonferroni correction). 
 
Tumor WHO histotype and grade, as well as lymphovascular invasion, showed 
neither significant difference among the three subgroups (Table 3) nor 
prognostic value. The most common WHO histotype in all cases was usual-
type, tubular adenocarcinoma. However, the signet ring cell type was more 
prevalent in CrD-SBCs, while the medullary type was more common in CD-
SBCs.  
 
CD-SBC cases were more infiltrated by CD3+ and CD8+ lymphocytes in 
comparison to CrD-SBC or spo-SBC cases (Figure 8). The median number of 
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CD3+ and CD8+ TILs was significantly higher in CD-SBCs than in either CrD-
SBCs or spo-SBCs (Table 3). A strong correlation between CD3+ and CD8+ 
TILs (Spearman correlation coefficient R=0.91, p<0.001) was found. SBC 
patients having a number of CD3+ TILs >15/HPF showed a better overall 
survival in comparison to those with ≤15 CD3+ TIL/HPF (Figure 7B and Table 
5). SBC cases having >9.5 CD8+ TIL/HPF showed a better overall survival in 
comparison to those with ≤9.5 CD8+ TIL/HPF (HR 0.08, 95% CI 0.02-0.35, 
p=0.001). At multivariable analysis, stage, CD3+ TIL and the clinical subgroup 
were independent prognostic factors (Table 4, model 2). 
 
4.2 HISTOLOGIC CLASSIFICATION OF SMALL BOWEL CARCINOMAS 
IN FIVE HISTOTYPES 
 
Histologic analysis showed predominance of gland-forming tumors over diffuse, 
mixed glandular/diffuse, medullary, or solid non-medullary cases (Table 6 and 
Figure 9). Survival analysis of these five tumor histotypes gave a trend for 
worse outcome of diffuse, mixed and solid non-medullary compared to 
glandular or medullary cases (Figure 10A). When diffuse, mixed and solid 
histotypes were pooled in a single group of 28 cases (Figure 10B), a significant 
survival difference emerged for this group in comparison with glandular cases 
(HR: 4.93, 2.23-10.89, p<0.001). Multivariable analysis confirmed a significantly 
improved survival of patients with glandular type SBC, independently of clinical 
group, TIL density and stage (Table 7). 
 
 
35 
 
35 
 
 
4.3 TUMOR CELL PHENOTYPE 
 
The distribution of the intestinal phenotypic markers CDX2, MUC2, CK20 or 
CD10, the gastric marker MUC5AC and the pancreatobiliary duct marker CK7 
among small bowel carcinoma subsets is outlined in Table 8, where 39 tumors 
with essentially intestinal phenotype (i.e. positive for CDX2, MUC2, CK20 
and/or CD10 while negative for both MUC5AC and CK7) were separated from 
the remaining 37 tumors expressing a metaplastic gastro-pancreatobiliary 
phenotype, either alone or admixed with the intestinal one (i.e. positive for 
MUC5AC and/or CK7 while being positive or negative for CDX2, MUC2, CK20 
and CD10). A general predominance of the intestinal phenotype among both 
celiac disease-associated and sporadic cases and of the non-intestinal (gastro-
pancreatobiliary or mixed) phenotype among CrD-SBC cases was observed 
(Figure 11). Intestinal phenotype was more frequently found in glandular 
(32/42, 76%) compared to in diffuse/mixed/solid cases (6/28, 21%, p<0.001). In 
particular, 11 of 13 mixed, 4 of 7 diffuse and 7 of 8 solid SBCs showed gastro-
pancreatobiliary markers expression. Of note, all of the 10 glandular cases with 
the non-intestinal phenotype occurred in CrD patients. 
 
Survival analysis showed a favorable influence of individual intestinal markers 
(especially CDX2 and MUC2) and a worse influence of gastro-pancreatobiliary 
markers. The pyloric and Brunner’s gland marker MUC6 was found in a small 
fraction (16%) of cases, including 2 CD-SBCs, 7 CrD-SBCs and 3 spo-SBCs, 
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without a significant difference among clinical groups (p=0.156) and without 
prognostic value (HR: 0.80, 0.30-2.13, p=0.654). 
 
Cumulative markers analysis showed better survival for patients with tumors of 
essentially intestinal phenotype compared with those expressing non-intestinal 
markers (in at least 10% of cells) (Table 8). This finding may contribute to the 
poor outcome of CrD-SBC patients, most of which (20/25, 80%) showed non-
intestinal marker expression. In a stage, sex and age inclusive survival analysis 
of 75 SBC patients, the favorable influence of intestinal phenotype was retained 
(hazard ratio: 0.30, 0.14-0.69; p=0.004), while it lost significance when the 
clinical group was also added to the model.  
 
4.4 MICROSATELLITE INSTABILITY IN SMALL BOWEL CARCINOMAS 
 
MSI was found in 25 out of 76 cases of SBC (33%), and no discordance was 
observed between immunohistochemical and molecular analysis. A significantly 
higher MSI frequency was found in CD-SBCs compared with either CrD-SBCs 
or spo-SBCs (Table 5). All MSI tumors showed a loss of both MLH1 (Figure 8, 
G-I) and PMS2 immunohistochemical expression while retaining MSH2 and 
MSH6 expression. MLH1 promoter methylation was detected in all but one MSI 
cases. The patient with an MSI SBC lacking the MLH1 promoter methylation 
was affected by CrD and had no history of familial cancer. Nineteen of 25 MSI 
cases (76%) showed >15 TIL/HPF in contrast to 9 of 51 non-MSI tumors (18%, 
p<0.001). At univariable analysis, MSI tumors showed a better overall survival 
in comparison to non-MSI tumors (Figure 12 and Table 5). Moreover, among 
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CD-SBC patients, MSI was able to separate two subgroups with a different 
stage (18% in stage III/IV for MSI in comparison to 75% of non-MSI, p=0.005) 
and different overall survival. However, in a multivariable analysis inclusive of 
age, sex, stage and clinical subgroup, MSI lost significant survival prognostic 
power (Table 4, model 3), which was retained (HR 0.31, 95% CI 0.10-0.98, 
p=0.046) when clinical subgroup was dropped from the model. It should be 
outlined that 9 of 28 high-TIL SBCs were non-MSI cases. These cases may 
contribute to explain the higher prognostic power of high TIL density compared 
to MSI status, as also highlighted by univariable survival analysis (Table 5). 
4.5 IMPACT OF MICROSATELLITE INSTABILITY AND TUMOR-
INFILTRATING LYMPHOCYTES ON PROGNOSTIC POWER OF 
HISTOTYPE AND PHENOTYPE 
 
When we found that both MSI and high TIL density were segregating among 
SBCs showing glandular or medullary histotype and intestinal phenotype, we 
investigated for any potential impact of MSI and/or high TILs on the prognostic 
power of histotype and phenotype. Separation of 25 cases showing MSI, 28 
cases with high TILs or 19 cases showing both MSI and high TILs from the 
remaining SBCs gave highly significant survival differences (hazard ratio: 0.22, 
0.08-0.64, p=0.005; hazard ratio: 0.09, 0.02-0.36, p<0.001 and hazard ratio: 
0.26, 0.12-0.57; p<0.001, respectively). Survival analysis of the 51 non-MSI or 
the 48 low TIL cases confirmed the importance of histologic structure and 
phenotype with an improved survival of glandular versus diffuse/mixed/solid 
cases (HR: 0.28, 0.12-0.63, p=0.002 among microsatellite stable cases and HR: 
0.40, 0.18-0.87, p=0.022 among low TIL cases, respectively), and of intestinal 
38 
 
38 
 
versus non-intestinal phenotype SBC cases (HR: 0.50, 0.23-1.08, p=0.080 and 
HR: 0.41, 0.19-0.89, p=0.023, respectively). 
 
4.6 PD-L1 IMMUNOHISTOCHEMICAL EXPRESSION IN SMALL BOWEL 
CARCINOMAS 
 
PD-L1 staining was observed in membranes and/or cytoplasm of some stromal 
immune cells (mostly macrophages), usually restricted to the tumor invasive 
margin, in 8 (6 MSI and 2 non-MSI) of the 23 CD-SBCs tested, in 5 of the 25 
CrD-SBCs, and in 5 of the 23 spo-SBC cases tested (Figure 13), without 
significant difference among the subgroups. However, only one SBC case, 
which was a MSI medullary cancer associated with CD, expressed PD-L1 in the 
tumor cell cytoplasm. 
 
4.7 GENE MUTATIONS IN SMALL BOWEL CARCINOMAS 
 
No BRAF mutation was observed in any case of SBC (Table 9). KRAS, NRAS, 
and PIK3CA mutations were detected in 23, 3 and 10 out of 76 cases, 
respectively. As expected, KRAS and NRAS mutations were mutually exclusive, 
while 6 SBC cases (8%), including 4 spo-SBCs, 1 CD-SBC and 1 CrD-SBC, 
showed concurrent mutations in PIK3CA and KRAS/NRAS genes. Most of the 
KRAS mutations were in codons 12 and 13, and were pG12V or pG13D. The 
rare NRAS mutations were in codons 12 or 61, whereas PIK3CA mutations 
were equally distributed in codons 542, 545, 546 and 1047. KRAS mutations 
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were more frequent in spo-SBCs compared with CrD-SBCs, while no difference 
was found between CD-SBCs and the other two subgroups (Table 9).  
 
P53 overexpression involving >50% of tumor cells did not differ among the three 
subgroups (Table 9). TP53 mutations were found in 17 of 47 SBC cases 
investigated (6 of 15 CD-SBCs, 3 of 17 CrD-SBCs and 8 of 15 spo-SBCs). 
TP53 mutations were found either in cases showing p53 overexpression (16 
cases) or complete lack of p53 immunostaining (1 case). TP53 mutations and 
MSI proved to be mutually exclusive (p=0.038); however, despite their wild-type 
TP53, seven (28%) MSI tumors showed p53 overexpression at 
immunohistochemistry. Most (88%) TP53 mutations were observed in exons 7 
and 8, only two cases showed TP53 mutations in exon 6, whereas no mutation 
was found in exon 5. In total, six of 8 non-MSI CD-SBC cases harbored TP53 
mutations.  
 
Five (7%) SBC cases were HER2+ at immunohistochemistry and revealed 
HER2 gene amplification (Table 9 and Figure 14). Histologically, all 5 HER2 
amplified cases were usual-type, tubular adenocarcinomas. Three HER2+ cases 
were jejunal tumors (2 CD-SBCs and 1 spo-SBC) and the remaining two were 
ileal CrD-SBCs. Three HER2 amplified SBC cases were TP53 mutated, two 
were KRAS mutated and one had MSI. KRAS, NRAS, PIK3CA and TP53 
mutations, p53 overexpression, and HER2 amplification showed no prognostic 
value. 
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4.8 SMALL BOWEL CARCINOMA EXPRESSION OF NUCLEAR β-
CATENIN AND SOX-9 
 
As shown in Table 10 and Figure 15A-B, nuclear β-catenin expression was 
significantly concentrated within the CD-SBC group, which differed significantly 
from the remaining SBCs. Interestingly, N-terminally directed antibodies failed 
to recognize nuclear β-catenin in 17/40 (42%) tumors where the protein was 
easily detected in the nucleus by C-terminal antibodies. Both N- and C- terminal 
antibodies recognized membranous β-catenin in normal non-tumor mucosa of 
the same cases, thus suggesting the possibility of a tumor-selective N-terminal 
β-catenin loss. This was found to be unrelated to patient background disease 
and survival (Table 10). Like nuclear β-catenin expression, the loss of MLH1 
expression (which overlapped perfectly with molecularly assessed microsatellite 
instability status) was also highly and selectively concentrated among CD-SBCs 
(p=0.001 vs remaining SBCs). In fact, a correlation was found among the whole 
small bowel cancer series between the distribution of the two changes 
(p<0.001). 
 
The nuclear expression of SOX-9, another Wnt-related transcription factor, was 
significantly correlated with that of β-catenin (p=0.005) and was also highly 
represented among CD-SBCs (Figure 15C), although less selectively than β-
catenin. Indeed, no significant difference for SOX-9 expression was found 
among clinical groups. A trend for SOX-9 to be more extensively expressed in 
intramucosal or superficial than in deeply invasive tumor growths was noted. 
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Univariate survival analysis of the whole series showed a significantly better 
survival for patients bearing nuclear β-catenin positive vs negative SBC, while 
SOX-9 failed to reveal prognostic relevance. The association of nuclear β-
catenin with more favorable outcome was retained in a stage, age and sex 
inclusive multivariable model (HR: 0.32, 0.13-0.75; p=0.010) or in a stage and 
histotype inclusive model (HR: 0.29, 0.13-0.65; p=0.003), while losing 
significance only when clinical groups were added to the model. However, when 
survival of 20 SBC patients showing both MSI and nuclear β-catenin was 
compared with that of 20 cases showing nuclear β-catenin in the absence of 
MSI, the latter group had a worse outcome (HR: 7.14, 2.00-25.00; p=0.002). In 
addition, among the 51 microsatellite stable cases, the 20 β-catenin positive 
SBC cases lacked any survival difference compared with 31 β-catenin negative 
SBC patients (HR: 0.66, 0.31-1.43; p=0.296). 
 
4.9 DYSPLASIA AND PRENEOPLASTIC CHANGES 
 
Evidence for residual adenomatous polypoid growth was obtained, within or 
adjacent to the superficial part of the neoplasm, in 10 of 25 spo-SBCs, 8 of 25 
CrD-SBCs and only one of 26 CD-SBCs. Focal flat dysplasia, usually adjacent 
to the invasive cancer focus, was detected in 4 CD-associated, 1 sporadic and 
5 CrD-associated SBCs (Figure 15D). Minute dysplastic foci were found, in 
addition, associated with mucosal metaplastic changes in 3 CrD-SBCs (see 
below). Total dysplastic lesions are summarized in Table 11, where it appears 
that nuclear SOX-9 (Figure 15E), found in 23/28 (82%) of cases investigated, is 
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the molecular marker most widely expressed in dysplasia, irrespective of clinical 
group, followed by p53 overexpression (15/29, 52%) and β-catenin (10/29, 
34%) (Figure 15F), with only 2 of 29 (7%) dysplastic lesions showing MLH1 
loss. On the contrary, the latter change occurred in 24/76 (32%) carcinomas, 
including 5 of the cases retaining MLH1 staining in the corresponding dysplasia 
(Figure 15G). This finding outlines a relatively late appearance of MSI status 
during carcinogenesis. 
 
Diffuse or patchy CD lesions, i.e. goblet-cell poor crypt hyperplasia plus 
increased intraepithelial lymphocytes, either isolated (5/25) or associated with 
villous atrophy (17/25), were seen in the majority (22/25, 88%) of CD-SBCs, 
both in cancer-adjacent and cancer-distant small bowel mucosa. Notably, 
nuclear SOX-9 expression, normally restricted to the deep lower half of crypts 
(Figure 15H), showed a prominent expansion to involve the upper half of the 
crypts in non-tumor mucosa of all 19 CD-SBCs investigated, sometimes 
reaching the crypt/villous junction or even to the superficial epithelium covering 
the flattened mucosa resulting from villous atrophy (Figure 15I). Care was 
taken to discard chromogranin-A reactive cells, usually showing SOX-9 positive 
cytoplasm in the absence of nuclear staining and scattered as single elements 
along the whole crypt-villous unit (Figure 15H). Interestingly, direct continuity of 
SOX-9 reactive crypt hyperplasia with dysplasia and intramucosal neoplasia 
was consistently seen (Figure 15E). No relevant change of nuclear β-catenin 
expression, which remained restricted to very few cells interposed with Paneth 
cells within the deepest crypts, was observed in SOX-9 positive crypt 
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hyperplasia. However, intense nuclear β-catenin appeared in adjacent 
dysplastic or neoplastic lesions (Figure 15F). 
 
While no preneoplastic change was identified in non-tumor mucosa of spo-
SBCs, metaplastic changes showing expression of the gastric foveolar marker 
MUC5AC and/or the ductal pancreatobiliary marker CK7 were extensively 
represented (86%) in the chronically inflamed, non-neoplastic mucosa 
associated with CrD-SBC, sometimes coupled with minute dysplastic or 
neoplastic foci (Figure 15J). Notably, 93% of the overt dysplastic lesions 
associated with CrD-associated carcinomas showed expression of CK7 and/or 
MUC5AC; moreover, the gastro-pancreatobiliary markers were concordantly 
expressed in metaplastic, dysplastic and invasive components of all but one of 
the 15 CrD-SBCs investigated (Figure 15K-M). 
 
4.10 IDENTIFICATION OF TWO EPSTEIN-BARR VIRUS (EBV)-POSITIVE 
SMALL BOWEL CARCINOMAS ASSOCIATED WITH CROHN’S DISEASE 
 
A lympho-epithelioma-like carcinoma (LEC) arising on a background of long-
standing CrD (corresponding to case #24 in Table 2) and showing prominent 
nuclear reactivity for EBER, high density of TILs (CD3+ TILs: 156 /HPF and 
CD8+ TILs: 100/HPF) and absence of MSI, was first identified (Figures 16). 
This cancer was diagnosed in the terminal ileum of a 63-year old male with a 
13-year history of ileal, fibrostenosing, active CrD (Figure 17) under treatment 
with oral corticosteroids and mesalazine. Briefly, during elective surgery for 
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subocclusive symptoms, a 15-cm ulcerated mass was detected in the surgical 
specimen, showing a LEC infiltrating the intestinal wall up to the subserosal 
adipose tissue, with four lymph node metastases, classified as stage IIIB 
(T3N2M0). After intestinal resection, the patient was treated with oral 
mesalazine, and he is now cancer-free 20 months after resection.  
 
As in the stomach, which is the most frequent site of EBV+ carcinomas in the 
gastrointestinal tract, a substantial number of such neoplasms do not show LEC 
histology but present instead with conventional-type glandular morphology, we 
searched for the presence of EBV in tumor cells, using EBER in situ 
hybridization, in our SBC series. A conventional-type adenocarcinoma 
associated with CrD (corresponding to case #11 in Table 2) was found to be 
diffusely EBER+ (Figure 18A). The newly found EBV+ SBC case was diagnosed 
in the terminal ileum of a 69-year old male patient in whom a concomitant 
diagnosis of ileal, fibrostenosing, active CrD was clinically and pathologically 
confirmed. The patient underwent surgery and a 3.7-cm ileal tumor was found in 
the surgical specimen. Histologically, the SBC featured a conventional glandular 
histology, infiltrating the intestinal wall up to the subserosa with no lymph node 
metastases, classified as stage IIA (T3N0M0). Similar to the LEC case, this 
glandular case showed high-TIL density (CD3+: 15.2/HPF and CD8+: 
14.9/HPF) and absence of MSI (Figure 18B). After surgery, the patient was 
treated with oral budesonide, and he is now in maintenance therapy with oral 
mesalazine and cancer-free 155 months after radical surgery.  
None of the remaining CrD-SBCs or of the 11 CD-SBC cases investigated 
showed tumor cell positivity for EBER.  
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The glandular EBV+ CrD-SBC showed a Q546R mutation of PIK3CA gene and 
no KRAS, NRAS, BRAF or TP53 mutations, while the LEC case showed no 
mutation of PIK3CA, KRAS, NRAS, BRAF or TP53 genes. Nuclear β-catenin 
expression was present in the LEC, but it was not found in the glandular case 
(Table 12).  
 
The intestinal marker MUC2 was extensively expressed in both EBV+ SBCs. 
The gastric foveolar cell marker MUC5AC was positive in a restricted minority of 
invasive tumor cells (<10%) limited to the superficial portion of the two EBV+ 
carcinomas, while it was lost in the more deeply invasive part of the SBCs.  
 
Both EBV+ SBCs were coupled with a smaller EBV+ adenoma component, 
which showed positivity for both MUC5AC (Figure 18C-D) and MUC2. In the 
two EBV+ cases, EBER positivity was also seen in restricted foci of apparently 
non-dysplastic, goblet cell-poor immature mucosa contiguous to frankly 
dysplastic lesions. In the non-dysplastic epithelium, only partial overlapping was 
found between EBER and MUC5AC expression (Figure 18E-F). 
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Table 3. Demographic and clinico-pathological features of all 76 small bowel carcinoma patients. 
 
 CD-SBC CrD-SBC Spo-SBC Overall  P-value 
P-Value Among 
Subgroups* 
N. 26 25 25  
Age at SBC diagnosis,  
median (25th-75th), yrs 53 (42-66) 59 (54-69) 65 (62-72) 0.004 
CD vs CrD: 0.102 
CD vs Spo: 0.005 
CrD vs Spo:0.491 
Duration of intestinal disorder at SBC 
diagnosis, median (25th-75th), months 17 (5-60) 156 (3-288) NA 0.024
   
Female, N (%) 16 (62%) 9 (36%) 8 (32%) 0.074  
Site, N (%)      
Duodenum 6 (23%) 1 (4%) 2 (8%)   
Jejunum 17 (65%) 1 (4%) 18 (72%) <0.001 
CD vs CrD:<0.001 
CD vs Spo: 0.367 
CrD vs Spo:<0.001 
Ileum 3 (12%) 23 (92%) 5 (20%)   
Stage, N (%)      
I 3 (11%) 3 (12%) 1 (4%)   
II 14 (54%) 9 (36%) 13 (72%)   
III 6 (23%) 8 (32%) 9 (36%) 0.588  
IV 2 (8%) 5 (20%) 2 (8%)   
NA§ 1 (4%) 0 0   
Local lymph node metastases, N (%) 8 (32%) 13 (52%) 11 (46%) 0.358  
Distant metastases, N (%) 2 (8%) 5 (20%) 2 (8%) 0.446  
Histologic type, N (%)      
Medullary CA 4 (15%) 1 (4%) 1 (4%)   
ADCA/usual 19 (73%) 19 (76%) 19 (76%) 0.343  
ADCA/mucinous 1 (4%) 0 3 (12%)   
ADCA/signet ring cell 2 (8%) 5 (20%) 2 (8%)   
Histological grade, N (%)      
Low grade (G1-G2) 15 (58%) 13 (52%) 19 (76%) 0.197  
High grade (G3-G4) 11 (42%) 12 (48%) 6 (24%)   
Lymphovascular invasion, N (%) 17 (65%) 20 (80%) 13 (52%) 0.111  
CD3+ TIL/HPF, median (25th-75th) 23.7 (7.9-65.8) 3.3 (1.7-7.0) 5.5 (1.4-19.9) <0.001 
CD vs CrD: <0.001 
CD vs Spo: 0.002 
CrD vs Spo:0.528 
CD8+ TIL /HPF, median (25th-75th) 18.6 (5.7-43.1) 1.0 (0.5-6.0) 4.0 (1.7-22.8) <0.001 
CD vs CrD:<0.001 
CD vs Spo:0.020  
CrD vs Spo: 0.053 
*significant if p<0.017 according to Bonferroni correction. §In one CD-SBC patient (case 24 in Table 1), who presented 
with a locally advanced cancer and died 12 months after surgery, incomplete data regarding lymph node status 
precluded assigning an AJCC stage. ADCA, adenocarcinoma; CA, carcinoma; CD-SBC, celiac disease-associated 
small bowel carcinoma; CrD-SBC, Crohn’s disease-associated small bowel carcinoma; HPF, high power field; NA, not 
applicable; Spo-SBC, sporadic small bowel carcinoma; TIL, tumor-infiltrating lymphocyte.  
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Table 4. Overall survival by multivariable Cox models of 75 small bowel carcinoma patients. 
 
 
  
MODEL 1@  
 
MODEL 2^ 
 
MODEL 3&  
 
 
 
Hazard ratio 
 (95% CI) 
 
P value 
 
Hazard ratio  
(95% CI) 
 
P value 
 
Hazard ratio  
(95% CI) 
 
P value 
 
Clinical groups  
 0.007  0.045  0.024 
     CD-SBC 1.00 (base)  1.00 (base)  1.00 (base)  
     CrD-SBC 6.77 (1.84 -24.94) 0.004* 4.36 (1.09-17.44) 0.037* 5.29 (1.34-20.90) 0.018* 
     Spo-SBC 2.92 (0.77-11.05) 0.115♣* 2.06 (0.50-8.52) 0.316▲* 2.39 (0.60-9.58) 0.218°* 
Age at SBC diagnosis 
(as continuous variable) 
1.01 (0.98-1.05) 0.399 1.02 (0.98-1.05) 0.337 1.01 (0.98-1-04) 0.529 
Sex (male vs female) 1.13 (0.46-2.76) 0.786 0.66 (0.26-1.70) 0.392 0.46 (0.40-2.46) 0.981 
SBC stage, III-IV vs I-II 7.84 (3.16-19.48) <0.001 9.08 (1.06-1.16) <0.001 8.38 (3.26-25.32) <0.001 
CD3+ TIL,  
>15/HPF vs ≤15/HPF 
- - 0.13 (0.03-0.58) 0.008 - - 
MSI - - - - 0.50 (0.15-1.67) 0.256 
@Model 1: LR chi2(5)=42.52, p-value<0.001; Harrel’s C=0.82; shrinkage coefficient=0.88. ^Model 2: LR chi2(6)=53.29, p-
value<0.001; Harrel’s C=0.86; shrinkage coefficient=0.89. &Model 3: LR chi2(6):43.94, p<0.001; Harrel’s C=0.82; 
shrinkage coefficient=0.86.*For post-hoc comparisons, significance after Bonferroni correction set at 0.017. ♣Hazard ratio 
(95% CI): 0.43 (0.19-0.96), P value = 0.040 versus CrD-SBC. ▲Hazard ratio (95% CI): 0.47 (0.21-1.05), P value = 0.067 
versus CrD-SBC.°Hazard ratio (95% CI): 0.45 (0.20-1.10), P value = 0.052 versus CrD-SBC. CD-SBC, celiac disease-
associated small bowel carcinoma; CrD-SBC, Crohn’s disease-associated small bowel carcinoma; HPF, high power field; 
MSI: microsatellite instability; SBC, small bowel carcinoma; Spo-SBC, sporadic small bowel carcinoma; TIL, tumor-
infiltrating lymphocyte. 
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Table 5. Microsatellite instability status and tumor-infiltrating lymphocytes: distribution 
among clinical subgroups and overall survival analysis on 76 small bowel carcinomas. 
 
 
£p=0.001 vs CrD-SBC or Spo-SBC; $p=0.001 vs CrD-SBC; ^p<0.001 vs CrD-SBC or Spo-SBC; Abbreviations: CD-
SBC, celiac disease-associated small bowel carcinoma; CrD-SBC, Crohn’s disease-associated small bowel 
carcinoma; HPF: high-power field; HR: hazard ratio; CI: confidence interval; , MSI: microsatellite instability; Spo-
SBC, sporadic small bowel carcinoma; TIL: tumor-infiltrating lymphocyte. 
  
  
 Distribution among clinical subgroups Total Survival analysis 
 CD-SBC CrD-SBC Spo-SBC  HR (95% CI) P value 
MSI 17/26 (65%)£ 4/25 (16%) 4/25 (16%) 25/76 (33%) 0.22 (0.08-0.64) 0.005 
CD3+ TIL >15/HPF 16/26 (61%)$ 4/25 (16%) 8/25 (32%) 28/76 (37%) 0.09 (0.02-0.36) <0.001 
MSI plus CD3+ TIL >15/HPF 14/26 (54%)^ 1/25 (4%) 4/25 (16%) 19/76 (25%) 0.26 (0.12-0.57) <0.001 
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Table 6. Histologic classification of the 76 small bowel carcinomas investigated. 
 
No significant histotype distributive difference among clinical groups was found. Abbreviations: CD-SBC, celiac 
disease-associated small bowel carcinoma; CrD-SBC, Crohn’s disease-associated small bowel carcinoma; 
Spo-SBC, sporadic small bowel carcinoma. 
 
Histotype Distribution among clinical groups Total 
 CD-SBC 
(n=26) 
CrD-SBC 
(n=25) 
Spo-SBC 
(n=25) 
 
Glandular 14 (54%) 13 (52%) 15 (60%) 42 (55%) 
Medullary 4 (15%) 1 (4%) 1 (4%) 6 (8%) 
Solid 3 (11.5%) 2 (8%) 3 (12%) 8 (11%) 
Diffuse 2 (8%) 4 (16%) 1 (4%) 7 (13%) 
Mixed 3 (11.5%) 5 (20%) 5 (20%) 13 (23%) 
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Table 7. Overall survival by a multivariable Cox model of the 75 small bowel carcinomas patients 
with complete stage data. 
 
 
 
Hazard ratio (95% 
CI) 
 
p value 
 
Clinical group 
 
0.033 
 CD-SBC 1.00 (base)  
   CrD-SBC 4.98 (1.35-18.34) 0.016* 
  Spo-SBC 2.48 (0.66-9.29) 0.176♣* 
Stage III-IV vs stage I-II 9.31 (3.30-26.26) <0.001 
CD3+ tumor-infiltrating lymphocytes >15/high-power 
field vs ≤15 
0.15 (0.03-0.69) 0.015 
Glandular histotype vs non-glandular$ 0.37 (0.16-0.84) 0.018 
 
Model: LR chi2(5)=56.72, p-value<0.001; Harrell’s C=0.87; shrinkage coefficient=0.91. *For post-hoc comparisons 
among clinical groups, significance after Bonferroni correction set at 0.017. ♣Hazard ratio (95% CI): 0.50 (0.22-1.14), 
p-value =0.098 versus Crohn’s disease- associated small bowel carcinomas. $Medullary histotype included among 
non-glandular cases. Abbreviations: CD-SBC, celiac disease-associated small bowel carcinoma; CrD-SBC, Crohn’s 
disease-associated small bowel carcinoma; Spo-SBC: sporadic small bowel carcinoma. 
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Table 8. Expression of phenotypic markers in 76 small bowel carcinomas: their distribution 
among clinical groups and prognostic value 
 
^p=0.004 vs CrD-SBC; £p=0.002 vs CrD-SBC ; §p=0.002 vs CrD-SBC ; $p=0.003, vs Spo-SBC; *p=0.004 vs 
Spo-SBC; °p=0.001 vs Spo-SBC; &versus remaining 37 cases expressing gastro-pancreatobiliary markers. 
Abbreviations: CD-SBC, celiac disease-associated small bowel carcinoma; CrD-SBC, Crohn’s disease-
associated small bowel carcinoma; Spo-SBC: sporadic small bowel carcinoma. 
  
 Distribution among clinical groups Total Survival analysis 
   
CD-SBC 
 (n=26) 
 
 
CrD-SBC 
 (n=25) 
 
 
Spo-SBC 
(n=25)  
Hazard ratio 
(95% confidence 
interval) 
p-value 
Cytokeratin 7 5 (19%)^ 15 (60%)$ 4 (16%) 24 (32%) 2.72 (1.18-6.29) 0.019 
MUC5AC 5 (19%) 13 (52%) 5 (20%) 23 (30%) 2.54 (1.08-5.98) 0.032 
CDX2 21 (81%)£ 9 (36%) 17 (68%) 47 (62%) 0.28 (0.13-0.63) 0.002 
MUC2 18 (69%) 12 (48%) 12 (48%) 42 (55%) 0.25 (0.12-0.53) <0.001 
Cytokeratin 20 13 (50%) 9 (36%)* 20 (80%) 42 (55%) 1.19 (0.57-2.50) 0.635 
CD10 8 (31%) 3 (12%) 11 (44%) 22 (29%) 0.66 (0.30-1.65) 0.302 
Intestinal phenotype 17 (65%)§ 5 (20%)° 17 (68%) 39 (51%) 0.39 (0.18-0.81)& 0.012 
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Table 9. Molecular alterations of the 76 small bowel carcinomas. 
 
     CD CrD Spo Overall  P-Value 
P-value among 
groups* 
SBC 26 25 25   
KRAS mutation, N (%) 8 (31%) 3 (12%) 12(48%) 0.021 
CD vs CrD: 0.173 
CD vs Spo: 0.258 
CrD vs Spo:0.012 
NRAS mutation, N (%) 1 (4%) 1 (4%) 1 (4%) 1.000  
BRAF mutation, N (%) 0 (0%) 0 (0%) 0 (0%) 1.000  
PIK3CA mutation, N (%) 4 (15%) 2 (8%) 4 (16%) 0.759  
HER2 amplification, N (%) 2 (8%) 2 (8%) 1 (4%) 1.000  
p53 overexpression (>50%), N (%) 12 (46%) 12 (48%) 13 (52%) 0.958  
*significant if p<0.017 according to Bonferroni correction; CD, celiac disease; CrD, Crohn’s disease; Spo, sporadic; 
SBC: small bowel carcinoma 
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Table 10. β-catenin and SOX-9 expression in small bowel carcinomas: distribution among clinical 
groups and survival analysis. 
 
^p<0.001 vs CrD-SBC or Spo-SBC; £p=0.001 vs CrD-SBC or Spo-SBC; *p<0.001 vs CrD-SBC and p=0.008 vs Spo-SBC; 
$versus remaining SBCs; §versus remaining C-terminal β-catenin positive cases;°All 17 MSI cases also had nuclear β -catenin 
among CD-SBC; as against only one of 4 among CrD-SBCs and 2 of 4 among Spo-SBCs. Abbreviations: CD-SBC, celiac 
disease-associated small bowel carcinoma; CrD-SBC, Crohn’s disease-associated small bowel carcinoma; Spo-SBC: 
sporadic small bowel carcinoma. 
  
 Distribution among clinical groups Total cases Survival analysis 
 CD-SBC CrD-SBC Spo-SBC  
Hazard ratio 
(95% confidence 
interval) 
p value 
Nuclear β-catenin, C-
terminal antibody 24/26 (92%)
^ 6/24 (25%) 10/25 (40%) 40/75 (53%) 0.30 (0.14-0.63) 0.002 
Nuclear N-terminal β-
catenin loss 10/26 (38%) 2/24 (8%) 5/25 (20%) 17/75 (23%) 0.49 (0.22-1.12)
$ 0.091 
 
among C-terminal  
β -catenin positive 
cases 
10/24 (42%) 2/6 (33%) 5/10 (50%) 17/40 (42%) 0.85 (0.24-2.97)§ 0.796 
SOX-9 expression 20/23 (87%) 11/22 (50%) 14/23(51%) 45/68 (66%) 0.70 (0.31-1.56) 0.380 
Microsatellite 
instability° 17/26 (65%)
£ 4/25 (16%) 4/25 (16%) 25/76 (33%) 0.22 (0.08-0.64) 0.005 
 
among C-terminal 
β–catenin positive 
cases 
17/24 (71%)^ 1/6 (17%) 2/10 (20%) 20/40 (50%) 0.14 (0.04-0.50) 0.002 
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Table 11. Analysis of dysplastic and metaplastic changes associated with small bowel 
carcinomas. 
 
$polypoid in one and flat in 4 cases; £polypoid in 8, flat in 5 and minute foci in metaplasia in 3 cases; &polypoid in 
10 and flat in 1 case. §p<0.001 vs either celiac disease-associated carcinomas or sporadic carcinomas. 
°Metaplastic phenotype was defined as extensive MUC5AC and/or cytokeratin 7 expression. Abbreviations: CD-
SBC, celiac disease-associated small bowel carcinoma; CrD-SBC, Crohn’s disease-associated small bowel 
carcinoma; Spo-SBC: sporadic small bowel carcinoma. 
 
  
 
 
CD-SBC 
 
CrD-SBC Spo-SBC Total 
Dysplasia 5/26 (19%)$ 16/25 (64%)£ 11/25 (44%)& 32/76 (42%) 
 Metaplastic phenotype° 0/5 (0%) 14/15 (93%) 2/10 (20%) 16/30 (53%) 
 β-catenin nuclear expression 5/5 (100%) 0/13 (0%) 5/11 (45%) 10/29 (34%) 
 SOX-9 expression 5/5 (100%) 10/13 (77%) 8/10 (80%) 23/28 (82%) 
 MLH1 loss 1/5 (20%) 1/14 (7%) 0/10 (0%) 2/29 (7%) 
 p53 overexpression 4/5 (80%) 7/15 (47%) 4/9 (44%) 15/29 (52%) 
Non-dysplastic mucosa     
 Metaplastic phenotype° 2/25 (9%) 19/22 (86%)§ 0/24 (0%) 21/71 (30%) 
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Figure 7. A) Kaplan-Meier overall survival estimates for all patients by clinical 
subgroup. B) Kaplan-Meier overall survival estimates for all patients by CD3+ 
tumor-infiltrating lymphocytes (TIL) density. P value is log-rank across subgroups. 
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Figure 8. Immunohistochemical detection of CD3, CD8 and MLH1. Immunohistochemical 
detection of CD3 showed numerous CD3-positive TILs in a CD-SBC (A). On the other 
hand, CD3 positivity was limited to a few cells in a CrD-SBC (B, original magnification 
x400) and a spo-SBC (C). Similarly, immunohistochemical detection of CD8 showed 
numerous CD8-positive TIL in a CD-SBC (D), in contrast to isolated CD8-positive cells in 
a CrD-SBC (E) and a spo-SBC (F). Immunohistochemical detection of MLH1 showed loss 
of expression in a CD-SBC (G), while MLH1 expression was retained by both a CrD-SBC 
(H) and a spo-SBC (I). Data are representative of staining performed in 26 CD-SBCs, 25 
CrD-SBCs and 25 spo-SBCs. 
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Figure 9. SBC histotypes. A) This glandular type CD-SBC is predominantly 
composed of well-formed tubular structures. B) This diffuse type CD-SBC is 
characterized by poorly cohesive cells, dispersed in a desmoplastic stroma as 
single elements or as small aggregates. C-D) A mixed type Crohn’s disease-
associated ileal carcinoma characterized by a combination of both glandular and 
diffuse patterns within the same tumor. In D, the same CrD-SBC expressing the 
gastric marker MUC5AC in both components. E) A non-medullary solid type CD-
SBC composed of nests of large, eosinophilic and atypical cells without intratumor 
T cell infiltration. F) This medullary-type CD-SBC is characterized by 
solid/trabecular growth of cells, a pushing margin, and prominent infiltration by 
numerous T lymphocytes (see CD3 immunostaining in the inset). 
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Figure 10. A) Kaplan-Meier survival estimates for all 76 SBC patients by 
histotype. Post-hoc comparisons (significance after Bonferroni correction set at 
p<0.005): a) significant differences: diffuse vs glandular: p<0.001; diffuse vs 
medullary: p=0.003; glandular vs mixed: p<0.001; b) non-significant trends: 
medullary vs mixed: p=0.013; medullary vs solid: p=0.064; glandular vs solid: 
p=0.088; c) non-significant differences: diffuse vs mixed: p=0.544; diffuse vs solid: 
p=0.170; mixed vs solid: p=0.401; glandular vs medullary: p=0.207. Notably, no 
difference was found between diffuse, mixed and solid histotypes, which were 
pooled in Figure 10B. B) Kaplan-Meier survival estimates for the 70 non-medullary 
SBC patients by glandular versus diffuse/mixed/solid histotype. 
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Figure 11. Phenotypic marker expression in SBC. A) Uniform and intense nuclear 
positivity for the intestinal transcription factor CDX2 in a glandular type CD-SBC. 
B) Luminal surface expression of the brush border marker CD10 in a CD-SBC. C) 
A sporadic SBC reactive for the intestinal marker CK20. D) Signet ring cell CrD-
SBC reactive for the goblet cell mucin MUC2. E) A glandular CrD-SBC extensively 
expressing the gastric foveolar marker MUC5AC. F) A mixed type CrD-SBC 
reactive for the pancreatobiliary duct marker CK7. 
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Figure 12. Kaplan-Meier overall survival estimates for all patients (A), CD-SBC 
patients (B), CrD-SBC patients (C) and spo-SBC patients (D) by microsatellite 
instability (MSI). P value is log-rank across subgroups.  
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Figure 13. An example of PD-L1 immunohistochemical detection. PD-L1 
immunohistochemical detection showing PD-L1 expression in membranes and/or 
cytoplasm of some immune cells (mostly macrophages), while tumor cells are negative 
(A, original magnification, x200 and enlarged in B, x400). This SBC was found in the 
jejunum of a patient with CD and harbored MSI. 
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Figure 14. An example of HER2 positive SBC. Histology of a mixed-type SBC (A), showing HER2 
positive by immunohistochemistry (B) and revealing HER2 gene amplification by FISH (C). This 
SBC was found in the ileum of a patient with CrD. 
  
63 
 
63 
 
 
Figure 15. Molecular/cellular marker expression and preneoplastic changes. A-B) Nuclear 
accumulation of β-catenin in a CD-SBC (A), to be compared with a membranous/cytoplasmic 
reactivity of a CrD-SBC (B). C). Intense SOX-9 expression in the tumor cell nuclei of a CD-
SBC. D) Evidence for residual high grade dysplasia overlying the superficial part of an 
invasive CD-SBC (arrowheads). E-F) Nuclear SOX-9 (E) and β-catenin (F) expression in a 
flat, low-grade, dysplastic lesion of a CD-SBC case. Note the villous atrophy and, in the inset 
of E), the extensive nuclear SOX-9 reactivity of hyperplastic crypts adjacent to dysplasia.      
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G) Same CD-SBC as in (D) showing discrepancy in MLH1 expression between the dysplastic 
(positive) and the underlying, invasive (negative) components. H) A normal jejunal mucosa 
adjacent to a sporadic SBC with nuclear SOX-9 expression restricted to the deep-half of the 
crypts. Note a few enteroendocrine cells with SOX-9 reactive cytoplasm and unreactive 
nucleus (arrows). I) SOX-9 nuclear expression in the atrophic mucosa distant from a CD-
SBC, showing a prominent SOX-9 expansion to involve the upper half of the crypts, the 
crypt/villous junction and even the surface epithelium. J) A focus of MUC5AC-positive, high-
grade dysplasia of a CrD-SBC case. K) A dysplastic lesion and an underlying small focus of 
diffuse type CrD-SBC (arrowheads), both concordantly reactive for CK7. L) An isolated, 
“microscopic” CK7-positive neoplastic lesion with focal stromal invasion in the small bowel 
mucosa distant from a “macroscopic” CrD-SBC. M) Diffuse and intense MUC5AC positivity of 
a polypoid adenomatous dysplasia adjacent to a CrD-SBC. 
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Figure 16 Lymphoepithelioma-like small bowel carcinoma associated with Crohn’s 
disease. A, Low-power histology revealing a solid poorly differentiated tumor. B, High-
power histology showing polygonal tumor cells, with vesicular nuclei, prominent nucleoli 
and eosinophilic cytoplasm, mixed with numerous lymphocytes and granulocytes. C, CD3 
immunostain confirming the high number of intratumoral T lymphocytes. D, Tumor cells 
immunoreactive for cytokeratin 8/18. E, Epstein–Barr virus (EBV)-encoded RNA (EBER) 
in-situ hybridization demonstrating EBV infection in neoplastic cells. F, EBER positive 
tumor cells in ametastatic lymph node. 
. 
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Figure 17. Small bowel adjacent to the carcinoma showing histologic features consistent with 
active Crohn’s disease  
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Figure 18. A) Diffuse EBER positivity (blue) of neoplastic nuclei in the glandular 
cancer (adenocarcinoma). B) Numerous CD8+ TILs (brown) scattered within the 
cancerous epithelia. C) Extensive EBER positivity of an adenomatous growth 
adjacent to the invasive cancer. Note the lack of EBER positivity of normal crypts in 
the lower part of the micrograph. D) Heavy cytoplasmic immunostaining of the same 
villous adenoma as of C), for the gastric foveolar marker MUC5AC. E, F) 
Consecutive sections of two villi in tumor-adjacent non-neoplastic mucosa showing 
many EBER+ epithelial cells (E). These EBER+ villous cells include both MUC5AC-
reactive (black arrows) and unreactive (arrowheads) cells; in addition, EBER- 
MUC5AC+ cells (empty arrows) are also found (F). 
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5. DISCUSSION 
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5.1 SURVIVAL DIFFERENCE BETWEEN CELIAC AND CROHN’S 
DISEASE CARCINOMAS 
 
This is the largest study of SBC in CD and the only one systematically 
comparing CD-SBCs, CrD-SBCs and spo-SBCs. We found that in patients 
undergoing surgery for SBC the underlying immune-mediated disorder 
represents a stage-independent prognostic factor. Survival analysis showed a 
significantly better prognosis of CD-SBC in comparison with CrD-SBC. 
However, in agreement with Palaskak-Juif et al. (52) we found no survival 
difference between CrD-SBC and spo-SBC. We observed a non-significant 
trend for improved overall survival of CD-SBC patients compared to an equally 
numerous spo-SBC subgroup. A significant survival improvement was 
observed by Potter et al. (30) by comparing a smaller CD-SBC group (n=17) 
with a much higher “control” group (n=51), mostly, though not exclusively, 
composed of sporadic cases. Of note, the five-year survival rate of our CD-
SBC patients was as high as 83%, suggesting a relatively indolent behavior of 
CD-SBC. 
5.2 PREVALENCE AND PROGNOSTIC INFLUENCE OF 
MICROSATELLITE INSTABILITY AND TUMOR-INFILTRATING 
LYMPHOCYTES 
 
Among the molecular alterations with prognostic impact, MSI, which is a 
consequence of deficient MMR, was significantly more frequent among cases 
of CD-SBC in comparison to CrD-SBC and spo-SBC. The MSI prevalence we 
found in CD-SBC (17/26 cases, 65%) is in line with that of previous studies by 
Potter et al. (30) (8/11, 73%) and Diosdado et al. (29) (6/9, 67%). With regards 
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to CrD-SBC, the low percentage of MSI in our cases (16%) is in agreement 
with those reported by Rashid et al. (10) (14%) and Svrcek et al. (37) (3%).  
We confirm, in a larger series, the favorable prognostic influence of MSI 
suggested by previous studies (29,30). Due to its unequal distribution among 
clinical subgroups, MSI lost significant prognostic power in a subgroup-
inclusive multivariable model. However, high TIL density, despite its high 
correlation with MSI and prevalence in CD-SBC, retained significant power in 
such a model. This finding seems relevant as TILs are known from CCR 
studies to be the main effector of MSI-related prognostic improvement (53,54). 
This suggests that TIL assessment may prove to be an appropriate parameter 
for SBC prognostic evaluation. In this regard, the presence of PD-L1 reactive 
immune cells in a subset (25%) of our SBCs, and in particular in MSI-positive 
SBC cases, seems interesting and is in line with the recently published data by 
Thota et al. (55), who observed PD-L1 expression on tumor cells and immune 
cells in 17% and 43% of their SBC cases, respectively. This findings may 
deserve further investigation in the light of the potential role of therapies 
targeting the programmed cell death (PD)/PD-L1 immune checkpoint pathway 
in SBC, as already demonstrated for colorectal or other solid cancers with 
MMR deficiency/MSI (56, 57).   
5.3 PROGNOSTIC POWER OF SBC HISTOTYPE AND PHENOTYPE  
 
Retention of intestinal phenotype and gland-forming capacity by SBC tumor 
cells was associated with better patient survival compared to acquisition of 
non-intestinal phenotype or non-glandular histologic structure. The prognostic 
power of glandular histology was found to retain significance in a multivariable 
model inclusive of stage, clinical subgroup and TIL density. When substituted 
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for glandular histology in the same model, the intestinal phenotype lost 
prognostic power, which, however, was retained when the clinical subgroups 
were eliminated from the model. It should be noted that the subgroup-
independent behavior of the glandular histotype fits with its relatively uniform 
distribution among the clinical subgroups, while the group-sensitive behavior 
of the phenotype couples with the high, selective expression of non-intestinal 
markers, associated with worse prognosis, among CrD-SBCs. The latter 
finding may contribute to the poor survival shown by CrD-SBC patients. The 
histotype and phenotype approaches proposed here offer new tools for SBC 
prognostic evaluation, and these should be added to the clinical subgroup 
characterization and MSI status. 
5.4 RAS, BRAF, PIK3CA, TP53 AND HER2 GENE ALTERATIONS  
 
In spo-SBCs we observed a higher prevalence (48%) of KRAS mutation than 
in CrD-SBCs, which might be accounted for by the lower percentage we found 
in the latter subgroup (12%) in comparison to those reported by Rashid et al. 
(10) (43%) and Svrcek et al. (37) (23%). With regards to CD-SBC, our study is 
the first assessing the frequency of KRAS mutation, which was found in 31% 
of cases. This finding, although by itself irrelevant for patient survival in our 
series, could be relevant in selecting patients in whom anti-EGRF targeted 
therapy could be beneficial (58). HER2 amplification, although restricted to 
only five cases, also seems worth being considered as a potential therapeutic 
target (20). 
We first demonstrated the presence of PIK3CA mutation in a subset (16%) of 
CD-SBC cases. However, there was no significant difference in PIK3CA 
mutation rate among the three subgroups and no prognostic relevance. No 
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significant difference was evident among the three subgroups for p53 
changes, either regarding protein overexpression or gene mutation. 
Of note, there was no BRAF mutation in any case, including those harboring 
MLH1 hypermethylation. BRAF mutations are reported to be absent or 
extremely rare in spo-SBC (35,59) and in CrD-SBC (37). This finding seems to 
rule out BRAF mutation in inducing MLH1 gene promoter methylation, which 
represents the almost exclusive cause of MSI in our non-familial SBCs. This 
conclusion is in contrast with the role which BRAF mutation plays in the 
majority of MSI sporadic colorectal cancers (60). Thus, the identification of a 
possible oncogene mutation activating a process of MLH1 gene silencing in 
SBC cases remains an open issue. 
5.5 β-CATENIN NUCLEAR EXPRESSION IS A HALLMARK OF 
CELIAC DISEASE-ASSOCIATED SMALL BOWEL CARCINOMAS 
 
Like MSI, the nuclear accumulation of β-catenin was also found to be highly 
prevalent among CD-SBCs and to be apparently associated with improved 
survival. This seemed surprising as, unlike MSI, nuclear β-catenin expression 
has been reported by studies of other neoplasms to imply a less than 
favorable prognostic influence (61-63). However, when among β-catenin-
positive SBCs, MSI and microsatellite stable cases were compared, or among 
microsatellite stable carcinomas, β-catenin-positive and negative cases were 
compared, the lack of favorable prognostic influence of β-catenin itself, in the 
absence of MSI, became evident. The distributive association we found, 
especially among CD-SBCs, between nuclear β-catenin expression and the 
prognostic favorable MSI status, might account for this misleading prognostic 
influence of β-catenin. Notably, such an association is at variance with CRC 
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findings, where nuclear β-catenin expression, highly prevalent among 
microsatellite stable cases, due to CTNNB1 or APC point mutations, has been 
reported to be rare in MSI cases (64). Instead of point mutations, large 
CTNNB1 N-terminal deletions have been reported to stabilize β-catenin in 
20% of sporadic SBCs (16), a finding we confirmed by selective N- versus C-
terminal β-catenin immunohistochemistry in our spo-SBCs and extended to 
about 40% of CD-SBCs. Whether additional stabilization mechanisms may 
account for the very high CD-SBC rate of nuclear β-catenin (around 90%) and 
for its association with MSI status, it remains to be further investigated.  
5.6 SOX-9 EXPRESSION IN SMALL BOWEL CANCER AND NON-
NEOPLASTIC MUCOSA 
 
We found that another Wnt-related protein, the SOX-9 transcription factor, was 
also highly expressed in SBCs, with a distribution comparable to that of 
nuclear β-catenin, at least among CD-SBCs. This finding seems relevant, as 
SOX-9 high expression has been reported in several cancers, including 
colorectal, gastric, pancreatic, hepatocellular, brain, lung and prostate cancers 
(65). In some of these cancers, SOX-9 expression was found to be associated 
with tumor progression, invasion and metastasis, a pattern not seen in our 
SBCs. However, an important SOX-9 role in carcinogenesis has also been 
proposed (65), at least in part through Wnt activation via frizzled and LRP 
receptor overexpression (66, 67). In keeping with this hypothesis, SOX-9 
overexpression has also been reported in some precancerous conditions, 
including metaplastic and dysplastic lesions of chronic H. pylori gastritis (68, 
69), chronic bladder injury (70) and early stages of colorectal tumorigenesis 
(65) as well as in ‘acute’ untreated adult CD (71). This led us to investigate 
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non-tumor mucosa of SBC-bearing patients for SOX-9 expression. In most 
CD-SBC cases we frequently observed signs of persistent mucosal damage, 
including atrophy of the villi, excessive intraepithelial T lymphocyte infiltration 
and goblet cell-poor, relatively immature, crypt hyperplasia, not unlike those 
reported in biopsies of some non-neoplastic adult CD patients, even when 
under gluten-free diet (72). Notably, multifocal extension of nuclear SOX-9 
expression, usually involving the upper half of the hyperplastic crypts was 
found in most CD cases investigated, even in the mucosa at a distance from 
the neoplasm. By itself, the topographic continuity we observed at some foci 
between SOX-9 positive crypt hyperplasia and intramucosal dysplastic or 
cancerous growths may be suggestive for a histogenetic link between such 
lesions. 
A role for SOX-9 in the mucosa repair process of persistent CD lesions seems 
conceivable considering its known role in intestinal mucosal repair from other 
types of damage (73). The SOX-9 activating role of NF-kB transcription factor, 
as ascertained, for instance, in experimental H. pylori gastritis (69), seems 
especially important. Indeed, NF-kB activity, in turn activated by pro-
inflammatory cytokines, has been shown to be enhanced in many immune-
inflammatory processes, including IBD and related carcinogenesis (74) as well 
as CD (75). In fact, a switch from the known SOX-9 role in adult stem cell 
modulation to cancer stem cell activation, often chronic injury promoted and 
involving constitutive oncogene activation or oncosuppressor gene silencing, 
has been suggested by several studies (65, 70, 76-78). 
75 
 
75 
 
5.7 DISTINCT HISTOGENESIS OF CELIAC DISEASE-ASSOCIATED 
AND CROHN’S DISEASE-ASSOCIATED SMALL BOWEL 
CARCINOMAS 
 
Our evidence of polypoid adenomatous remnants in the superficial part of 
CrD-SBCs and spo-SBCs supports the hypothesis that the adenoma-
carcinoma sequence, well known from colorectal neoplasms, is also operative 
for these two types of SBC (37, 79, 80). In CD-SBC we obtained evidence for 
a possible adenomatous polyp origin in only a single case, thus confirming the 
previous finding (36, 81) of a substantial lack of such lesions in Cd cases, 
while we found four CD-SBCs with flat dysplasia reactive for both nuclear β-
catenin and SOX-9.  
Metaplastic changes showing the same gastric and/or pancreatobiliary 
phenotype as found in the associated cancer were frequent in dysplastic or 
non-dysplastic mucosa adjacent to CrD-SBCs, though not to CD-SBCs or spo-
SBCs. This finding may suggest a precancerous role of such lesions in CrD. 
Thus, two distinct histogenetic processes seem at work for CD-associated and 
CrD-associated SBCs, starting from immature crypt hyperplasia or epithelial 
metaplasia, respectively.  Although a more extensive, prospective and 
systematic search for hyperplastic, metaplastic and dysplastic lesions is 
warranted for a better understanding of SBC histogenesis in the two types of 
immune-inflammatory conditions we studied, the present findings may indicate 
promising lines of investigation to identify preneoplastic lesions of potential 
help in early cancer diagnosis. 
  
76 
 
76 
 
5.8 EPSTEIN-BARR VIRUS POSITIVE ILEAL CARCINOMAS 
 
A small group of medullary-type cancers, i.e. a solid structure with well 
demarcated “pushing” borders, found to have a good prognosis in accordance 
with previous studies (82-84), were distinct from solid non-medullary cancers. 
As expected, all SBCs with medullary-type histology had high TILs and five of 
the six cases also harbored MSI. The single medullary-type microsatellite 
stable case was tested with EBER in situ hybridization, finding it to be diffusely 
positive. Therefore, we searched for the presence of EBV, using EBER in situ 
hybridization, in tumor cells of all CrD-SBCs and a second case of EBV+ ileal 
SBC was detected. Unlike the first case, which was suspected because of a 
LEC histology, this case showed a conventional, non-distinctive, gland-forming 
structure. Both EBV+ cases turned out to have increased TILs despite the lack 
of MSI status, the main cause of high TILs in SBCs. In keeping with the 
molecular changes known to be involved in EBV+ cancers (85), we detected a 
PI3KCA gene mutation in the glandular histology case, nuclear ?-catenin 
expression in the LEC case, and the absence of TP53 mutations in both 
cases. Both EBV+ SBC patients had a favourable post-operative prognosis. 
This is an interesting finding considering the generally poor prognosis of CrD-
SBC patients, with a median survival of 28 months in our series. 
In both EBV+ SBC cases we detected a clear-cut EBER signal also in 
adenomatous dysplastic (non-invasive) lesions associated with the cancer 
growth as well as in small foci of iuxta-tumoral epithelium apparently lacking 
signs of dysplasia, a finding which may support the hypothesis of an initiating 
or very early direct role of EBV in the carcinogenetic process (85-88). The 
reactivity of EBV+ adenomatous components for the gastric foveolar cell 
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marker MUC5AC, known to be expressed in about half of EBV+ gastric 
cancers (42, 85, 87, 88), and shown to be also largely expressed in CrD-SBCs 
(89 and present study), is also particularly interesting. However, our detection 
of EBV in both MUC5AC+ and MUC5AC- non-dysplastic epithelium, likely the 
earliest site of viral infection during the carcinogenetic process, does not 
support MUC5AC expression or a foveolar-type metaplastic change of ileal 
enterocytes as a needed prerequisite for latent viral infection. Interestingly, 
EBV was reported to be the most prevalent intestinal viral infection in 
inflammatory bowel disease, and it has been shown to spread from immune to 
epithelial cells (90). However, in infected intestinal epithelial cells of cancer-
free inflammatory bowel disease patients, EBV usually establishes a 
productive, lytic phase of its life cycle without expression of latency-associated 
EBER (90), known to have oncogenic properties by promoting cellular growth 
and modulating innate immunity in EBV-associated cancers (85). Therefore, 
EBV+ carcinomas may occur in the ileum of CrD patients and are 
characterised by increased TILs in the absence of MSI, either with LEC or with 
a more conventional glandular histology. EBV infection should thus be 
investigated in such cancers irrespective of their histologic type, considering 
the better prognosis these neoplasms seem to show. 
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5.9 CONCLUSIONS 
 
The role of chronic inflammation in the genesis of intestinal cancer is well known 
(1). As both CD and CrD are T helper 1-mediated disorders, the prominent 
differences revealed in SBCs arising in these two disorders are surprising. 
However, it should be recalled that the inflammatory process implicated in CD and 
CrD shows substantial differences in terms of types of inflammatory cells and 
cytokines involved (91,92). Interestingly, all but one of our CD-SBC cases arose in 
non-refractory CD, a finding at variance with the origin of enteropathy-associated 
T-cell lymphoma (93). However, the median age at CD diagnosis of our CD-SBC 
patients (49 years) was two decades higher than that reported for Italian adult 
cancer-free CD patients (28 years) (26), confirming that a delayed CD diagnosis 
may predispose to an increased risk of neoplastic complications in general, and of 
SBC in particular. A delayed CD diagnosis may also contribute to the apparently 
low interval (17 months) between CD diagnosis and SBC detection. 
We do acknowledge that the present study has some limitations, the most 
important being its inherently retrospective nature. However, the involvement of 
centres with long-term referral experience in the field, which were following agreed 
guidelines, was a guarantee of data quality. 
In conclusion, although both CD-SBC and CrD-SBC arise from an inflammatory 
background, they differ substantially in prognosis, tumor cell phenotype, MSI/TIL 
status, Wnt pathway activation, and mucosal precursor lesions. 
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5.10 FUTURE PERSPECTIVES 
 
This PhD study identified specific histopathological, molecular and prognostic 
features of SBCs arising in celiac patients that suggest biological and clinical 
similarities with those described in CRC showing MSI and CpG Island Methylator 
Phenotype (CIMP). Recently, the Consensus Molecular Subtype (CMS) 
Consortium proposed the current best description of CRC heterogeneity at the 
gene-expression level, after analysis of 18 different CRC gene expression 
datasets (94). This transcriptomic classification enables the categorization of most 
CRCs into one of the four robust subtypes. Most CRCs with MSI cluster in the 
CMS1 group (MSI immune subtype, 14%), which is characterized by 
hypermutation, hypermethylation, enrichment for BRAFV600E mutations and 
evidence of strong immune activation (immune response, PD1 activation, natural 
killer (NK) cell, T helper 1 cell and cytotoxic T cell infiltration signatures), 
consistent with pathological descriptions of prominent CD8+ TILs. Next, CRCs with 
chromosomal instability can be classified into three groups based on gene 
expression signals: CMS2 (canonical subtype, 37%); CMS3 (metabolic subtype, 
13%); and CMS4 (mesenchymal subtype, 23%).  
Therefore, the next step of this project will be to evaluate the presence of CIMP in 
our series of CD-SBCs collected by the Small Bowel Cancer Italian Consortium 
and, for the same samples, to generate RNA sequencing data in order to compare 
the transcriptional signatures of CD-SBC with the four CMS of CRC. The final goal 
of the project will be to give new insights of clinical and therapeutic interest to 
guide CD-SBC management. 
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